Differential effects of four intramuscular sedatives on cardiorespiratory stability in juvenile guinea pigs (*Cavia porcellus*)

Ryan P. Sixtus¹, Cholawat Pacharinsak², Clint L. Gray¹, Mary J. Berry¹, Rebecca M. Dyson¹∗

¹ Department of Paediatrics and Child Health, & Centre for Translational Research, University of Otago, Wellington, New Zealand, ² Department of Comparative Medicine, Stanford University, Stanford, CA, United States of America

*becs.dyson@otago.ac.nz

Abstract

Background

Non-invasive physiological monitoring can induce stress in laboratory animals. Sedation reduces the level of restraint required, thereby improving the validity of physiological signals measured. However, sedatives may alter physiological equilibrium introducing unintended bias and/or, masking the experimental outcomes of interest. We aimed to investigate the cardiorespiratory effects of four short-acting sedatives in juvenile guinea pigs.

Method

12 healthy, 38 (26–46) day-old Dunkin Hartley guinea pigs were included in this blinded, randomised, crossover design study. Animals were sedated by intramuscular injection using pre-established minimum effective doses of either alfaxalone (5 mg/kg), diazepam (5 mg/kg), ketamine (30 mg/kg), or midazolam (2 mg/kg) administered in random order with a minimum washout period of 48 hours between agents. Sedative depth, a composite score comprised of five assessment criteria, was observed every 5-min from dosing until arousal. Physiological monitoring of cardiorespiratory status included measures of heart rate, blood pressure, respiratory rate, and peripheral microvascular perfusion.

Results

Ketamine and alfaxalone were most effective in inducing stable sedation suitable for physiological monitoring, and diazepam less-so. Midazolam was unsuitable due to excessive hypersensitivity. All sedatives significantly increased heart rate above non-sedated control rates (*P*<0.0001), without altering blood pressure or microvascular perfusion. Alfaxalone and ketamine reduced respiratory rate relative to their control condition (*P*<0.0001, *P*= 0.05, respectively), but within normative ranges.
Introduction

Many routine physiological assessments in laboratory animals require some level of restraint, either chemical or mechanical, to enable data acquisition, however, neither option can be considered optimal. Mechanical restraint may induce significant physiological stress, impairing the quality and validity of the assessments to be performed, whereas chemical restraint, either inhalational or injectable anaesthesia, may be confounded by complexities associated with the route of administration (e.g., vascular access in guinea pigs) [1, 2]. Additionally, the side-effects of anaesthesia include cardiovascular and respiratory depression, thereby limiting its use for a range of physiological studies [2–4]. Short-acting sedative agents may therefore offer a compromise, mitigating the confounding effects of manual restraint or full anaesthesia without abolishing key cardio-respiratory outcomes of interest.

Despite their wide utility, the cardiorespiratory impact of short acting sedatives in laboratory species remains largely unresolved [5]. The favoured sedatives change depending on procedures being performed, depth of sedation required, and the conventions of specific laboratories. Commonly used sedatives act on a range of different pathways, their use determined by the strength of on- and off-target effects. Agents such as alfaxalone and benzodiazepines act on GABAergic pathways to depress cortical function [6], whereas ketamine and nitrous oxide act on N-methyl-D-aspartate (NMDA) glutamatergic pathways to inhibit cortical excitability [7]. Alfaxalone has been frequently used as an induction agent, and recently has been used to achieve sedation for short duration non-noxious procedures while maintaining stable core body temperature and heart rate (HR) [8]. Benzodiazepines like midazolam and diazepam, are often combined with opioids or alpha-2 agonists (e.g., Medetomidine-Midazolam-Fentanyl (MMF)) to offset their lack of analgesic properties [6]. Benzodiazepines, however, also produce off-target vasodilation, which alters cardiovascular function [6, 8], limiting their usefulness in cardiovascular studies. Ketamine is effective in producing dissociative sedation and effective analgesia with limited cardiorespiratory depression but is also often paired with an alpha-2 agonist (e.g., medetomidine) to counter the effects of ketamine on muscle tone and movement [6]. The effects induced by these various sedatives are often short in duration (<1h) and limited in their sedative depth, such that only short duration, minimally invasive procedures can be performed.

Guinea pigs (Cavia porcellus) are a common laboratory species, used for a wide variety of research modalities [2]. They are, however, notoriously difficult to safely and effectively anaesthetise [1]; and this is also true for sedation. A lack of easily accessible venous access requires that injectable agents are safe for subcutaneous (SC) or intramuscular (IM) administration. IM administration of ketamine, for example, can produce skin irritation and tissue necrosis around the injection site [9], frequently resulting in self-mutilation following sedation [10]. Furthermore, once sedated, physiological responses in guinea pigs are notoriously unpredictable [11]. This can confound comparisons of physiological effects between species, and requires species-specific investigations to characterise the physiological effects of sedative
agents [8]. Finally, there is limited research to offer an ‘ideal’ sedative agent that does not have associated negative cardiorespiratory effects. We have therefore sought to characterise a) the cardiorespiratory effects, and b) the sedative stability, of four different commonly used sedative agents in guinea pigs.

Material and methods

Sedatives

Alfaxalone (10 mg.mL$^{-1}$, Alfaxan Multidose, Jurox, UK), diazepam (5 mg.mL$^{-1}$, Ilium diazepam, Troy Laboratories, Australia), ketamine (100 mg.mL$^{-1}$, Phoenix Pharm, NZ), midazolam (5 mg.mL$^{-1}$, Hypnovel, Roche Products, NZ).

Animals

All procedures were approved by the University of Otago, Wellington Animal Ethics Committee, and conformed to Health Research Council of New Zealand code of practice for the care and use of animals for scientific purposes, and are reported according to the ARRIVE guidelines [12]. Outbred, SPF Dunkin Hartley guinea pigs were sourced from the Biomedical Research Unit, University of Otago Wellington. To prevent litter bias, no more than 2 pups/sex/litter were used in any arm of the study. Guinea pigs were housed individually in a 12:12hr light- and temperature-controlled environment, with ad libitum access to standard guinea pig chow (Specialty Feeds, Glen Forrest, Australia) and vitamin C-enriched water (1 g.L$^{-1}$).

Study I—sedative trial. Twelve age-matched adolescent Dunkin Hartley guinea pigs (male (n = 6) and female (n = 6); mean age: 38d, (26-46d); mean weight: 364g (287-428g)) were included in this randomised crossover design study [13]. Sequence of sedation treatments was allocated using a computerised method (RAND function in Microsoft Excel) at commencement of study [14].

Study II—normative blood pressure. Twenty age-matched animals (male (n = 10) and female (n = 10); mean age: 38d (34-41d); mean weight: 362g (314–423)) were included for the purpose of establishing normalised systolic blood pressure (SBP) ranges in non-sedated juvenile Dunkin Hartley guinea pigs. Animals of corresponding age to Study I were randomly selected from the colony. Due to movement associated with NIBP cuff inflation, recordings were not available for n = 3 males and n = 3 females (due to excess movement and subsequent inability to obtain clear pulse and occlusion recordings). Thus, normative data is based only on those animals with a completed NIBP trial (male (n = 7) and female (n = 7); mean age: 38d (34-41d); mean weight: 356g (314–423)).

Procedure

Study I—sedative trial. Animals underwent five cardiovascular assessments, one under each sedative, and one conscious control (measures performed in non-sedated animals; no vehicle injection given) in random order. Sedatives assessed included alfaxalone (5mg.kg$^{-1}$), diazepam (5mg.kg$^{-1}$), ketamine (30mg.kg$^{-1}$), and midazolam (2mg.kg$^{-1}$). Dosage was guided by published reports [15], and veterinary practice (co-author CP; and Institutional Veterinarian—University of Otago). Where a range of dosages was reported, a dose-optimisation study was performed (data not presented). Each trial was completed at the same time of day to minimise circadian bias. At commencement of each trial, animals were assigned an American Society of Anaesthesiologists Veterinarian Technicians Score (ASA-VTS) based on physical examination (ASA I: minimal risk–ASA V: extreme risk) [8], and baseline measures of sedation/activity were recorded according to five parameters: movement, body tone, reaction to
manipulation, posture, and righting reflex (Table 1). These five assessments were summed in an unweighted manner to provide an overall cumulative sedative depth, with a range of 0–19, where “0” represents normal guinea pig behaviour, and higher scores reflecting greater sedative depth, “19” reflecting excess sedation. In addition to these parameters, observations outside of these parameters were noted under the categories of ambulatory, chewing, hyperactive, change in respiration, squinting, shivering, twitching, uncoordinated, and vocalisation as more subjective markers of behaviour outside of the formal monitoring matrix in order to fully capture animal’s state during the trial.

After baseline assessments of activity, animals were lightly restrained and sedative dose administered, before being placed in a quilt-lined cage for sedatives to take effect with minimal tactile, auditory or visual stimulation. All sedatives were provided by IM injection in the hindlimb(s). Where drug volume exceeded 0.3 ml.kg⁻¹ (diazepam, midazolam), doses were split between both legs [15] Injection sites were additionally alternated between trials to minimise potential discomfort from prior injections. Sedative depth was assessed in 5 min intervals from injection until completion of sedation. Sedation duration was calculated from observed onset of sedation through to arousal of the animal, with the majority of monitored signs returning to “normal” (Table 1). At onset of sedation, animals were transferred to a heated surface inside a temperature- and humidity-controlled chamber (25˚C; 30%RH) for cardiovascular assessment.

Cardiovascular assessment consisted of electrocardiography (needle electrode, ADInstruments, Dunedin, New Zealand) positioned over the inferior sternum and interscapular sites (earth: right rump) [16], SBP (non-invasive blood pressure, rat tail cuff, ADInstruments), positioned over right forelimb, and microvascular perfusion measured over proximal (interscapular) and distal (dorsal ear) skin sites using laser Doppler flowmetry (LDF; Probe 457, PeriFlux 5001, Perimed, Jarfalla, Sweden) affixed to depillated skin sites using modified TCO₂ fixation rings and double sided tape [17]. Respiratory rate was additionally measured using a pulse transducer (ADInstruments) positioned on the anterior abdominal wall, below the level of the diaphragm. Throughout the trials, animals were minimally restrained as required, to avoid excess tactile stimulation by assessors.

Animals were recovered for 48hr between trials to allow complete drug washout and recovery between trials. Upon recovery form each trial, animals received a body weight measurement, alongside a measure of wellbeing (B.A.R. [bright, alert, responsive] score and general clinical signs [inactive, hunched posture, coat rough, inflammed depilation sites, irritation of

| Score | Movement | Body Tone | Reaction to Manipulation | Posture | Righting Reflex |
|-------|----------|-----------|--------------------------|---------|-----------------|
| 0     | Normal coordinated movement | Rigid, hunched, waking tone | Normal reaction | Normal | Regained sternal recumbency immediately |
| 1     | Coordinated movement | Relaxed but upright, muscle tone present | Decreased response (flinch/movement/noise) | Head up but sitting | Regained sternal recumbency within 5-10s |
| 2     | Uncoordinated movement | Drowsy, recumbency, floppy | Minimal response (slight flinch/movement) | Head down sternal recumbency | Attempted to regain sternal recumbency but failed |
| 3     | Infrequent uncoordinated movement | Sedate, Atonal | No response | Lateral recumbency | Did not attempt to reposition |
| 4     | Infrequent weak uncoordinated movement | | | Dorsal recumbency but responsive to stimuli |
| 5     | No movement | | | Dorsal recumbency and unresponsive |

Total score of 0 corresponding to an awake, alert and coordinated animal; a total score of 19 corresponding to a deeply sedated, atonal and unresponsive animal.

https://doi.org/10.1371/journal.pone.0259559.t001
an injection sites, and dehydration; normal = 0, and 1, 2, 3 for increasing severity). An overview of the study design is presented in Fig 1.

Study II—normative blood pressure. Animals were randomly selected from the colony for one session of NIBP monitoring to establish normative SBP outside of Study I population and in the absence of additional physiological measures. Animals were relocated to the experimental room and placed in a quilt lined box to acclimate to the new surroundings for 20 min. They were then placed on a heated surface and lightly restrained as per Study I. An NIBP cuff was positioned over the right forelimb and, following a settling period of 30 min, inflated in 5 min intervals until three artefact-free recordings of SBP were obtained or 60 min had elapsed. Normative blood pressure recordings were assessed as per Study I.

Data analysis

ECG, NIBP, and respiration were sampled using PowerLab (ADInstruments) at a rate of 1 k.s⁻¹, with an analogue notch filter applied, and recorded in LabChart (ADInstruments). HR and respiration were derived using peak-to-peak analysis. LDF collected alongside central cardiovascular assessments was recorded at 32 Hz with a time constant of 0.03 s, and assessed in arbitrary perfusion units (PU; equipment calibrated prior to each experimental day) and analysed using custom software (PSW2; Perimed). In order to limit confounding effects of probe temperature on the cutaneous vascular response to sedatives, LDF measures were taken without controlling for probe temperature, according to established protocols [17–19].

Due to logistical constraints (e.g., level of consciousness) in blinding the experimenter (RPS) to all conditions, the experimenter was blinded to the identity of the sedative agent used both at the time of administration and during data analysis. The clinical condition of the animals was verified by a second experienced assessor (RMD), also blinded to experimental group at time of analysis. Whilst recorded continuously, cardiovascular, respiratory and microvascular perfusion measures were assessed across three separate epochs during sedation, with a 60 s window of representative, artefact-free data selected for further analysis.

Statistical analyses

Normality was assessed and confirmed using the Kolmogorov-Smirnov normality test. GraphPad Prism 7.04 (GraphPad Software, California, USA) was used for statistical analysis and generation of figures. Data were analysed using repeated measures mixed-effects or two-way ANOVA, with time or sedative treatment as the main factors. When compared to control,
cumulative sedative depth scores were truncated to key timepoints (‘baseline’, ‘removed from cage’, ‘physiological measures 1’ (P1), physiological measures 2’ (P2), ‘back to cage’, and ‘end’) to ensure comparison across the different durations of each sedative. Results were deemed statistically significant at $P \leq 0.05$ and reported as ±95% CI unless otherwise stated.

**Data availability**

All relevant data associated with sedative depth and cardiorespiratory findings are included in the paper and/ or its supplementary information files. S1–S5 Tables provide the individual data for each monitored sign for sedative depth data. The raw data files (recordings) supporting the cardiorespiratory findings of this study are available from the authors on reasonable request.

**Results**

**Study I: Animal and sedative characteristics**

**Animal characteristics.** Twelve animals completed the randomized sedation trial (*Study I*). The combined physical characteristics are presented in Table 2. Animal weight at each treatment were not different from control ($P = 0.45$). 24hr weight change (%) was not different between treatments (Table 2), with all animals, on average, gaining weight over the first 24 hours after sedation across all treatments. The mean age at study start in Study I was 33d with a standard deviation of ±4 days. Average age (±S.D.) for each treatment was not different from control, or between treatments ($P = 0.85$; control 37 ±6d, alfaxalone 38±4d, ketamine 37±5d, midazolam 36±5d, diazepam 38±4d). Of the 20 animals selected for the normalized blood pressure trial (*Study II*), useable data characterising non-invasive measures of SBP in a non-sedated animal habituated to handling were acquired in fourteen.

Both diazepam (3 instances) and ketamine (1 instance) were associated with instances irritation of the injection site. This presented as dragging of the hind limb following arousal from sedation, and scratching and chewing of the affected limb. This did not appear to be associated with tenderness of the site and there was no obvious swelling of the limb. In most instances, this resolved within 24 hours of administration (1 animal had persistent irritation (~4 days) associated with diazepam injection). This is in line with earlier reports that IM ketamine and diazepam may drive tissue irritation and even necrosis at the injection site. No necrosis was observed at injection sites following any of the sedatives, however animals were not observed long-term beyond the study period to capture this data. Doppler/ECG monitoring sites showed mild irritation (dry, red skin) in some animals, likely from repeated shaving/depilation, however this happened in relatively few animals and did not appear to effect signal acquisition.

| Table 2. Animal characteristics for alfaxalone, diazepam, ketamine and midazolam. |
|---------------------------------|---------------------------------|----------------|----------------|
| | Male | Female | 24hr weight change (%) | 24hr BAR score |
|---------------------------------|---------------------------------|----------------|----------------|
| Weight (g) (n = 6) | Weight (g) (n = 6) | | |
| Control | 362.5±47.0 | 360.0±43.6 | 1.36±1.23 | 0 |
| Alfaxalone | 367.0±44.9 | 340.8±36.8 | 1.23±3.88 | 0 |
| Diazepam | 375.2±41.9 | 360.5±37.8 | 1.14±3.78 | 0 |
| Ketamine | 371.3±59.9 | 359.0±42.6 | 1.04±3.82 | 0 |
| Midazolam | 365.8±36.1 | 365.2±38.9 | 1.09±2.92 | 0 |
| Normative Control | 341.0±67.8 | 355.3±23.1 | N/A | N/A |

24hr weight change is displayed as mean±S.D.

https://doi.org/10.1371/journal.pone.0259559.t002
Sedative characteristics over time. All drugs produced significant changes in the cumulative sedative depth score in comparison to pre-sedation baseline (Fig 2; contributing measures individually reported in S1–S5 Tables). The most rapid sedation occurred under alfaxalone (5.16 ± 0.32 min), with ketamine (6.16 ± 1.05 min) and midazolam (6.44 ± 1.39 min) also producing rapid sedation, whereas onset of sedation under diazepam was significantly longer than other sedatives (12.25 ± 1.46 min; P = 0.0006). Sedation duration was similar between alfaxalone, diazepam and midazolam (27.14 ± 1.52 min, 33.00 ± 3.31 min and 28.15 ± 3.41 min, respectively), with ketamine lasting significantly longer than both alfaxalone and midazolam (41.08 ± 5.02 min; P = 0.0013; P = 0.016), but not diazepam (P = 0.15). Peak effects for ketamine and alfaxalone occurred with onset (comparison to baseline: ~5 min, P < 0.0001 for both), whereas peak effects occurred around 10- and 15-min for midazolam and diazepam, respectively (P < 0.0001 and P = 0.0005, respectively). Ketamine produced the deepest sedation, closely followed by alfaxalone (16.7 ± 0.6 and 13.9 ± 2.2 out of 19, respectively; P < 0.0001). Diazepam and midazolam produced shallower sedation (9.3 ± 2.1 and 7.6 ± 2.7). In the absence of drugs,

![Fig 2. Cumulative sedative depth across the course of physiological monitoring for each condition: Control, alfaxalone, diazepam, ketamine, midazolam.](https://doi.org/10.1371/journal.pone.0259559.g002)
control animals also demonstrated a significant calming effect after 20 min of light restraint (20 min: 3.7±2.2, \(P = 0.019\); 25 min: 4.2±2.0, \(P = 0.0041\); 30 min: 5.4±2.8, \(P = 0.0083\)).

**Sedative characteristics in comparison to control.** All drugs produced significant changes in the cumulative sedative depth score in comparison to the control condition (Table 3). Baseline sedative scores were not different from control. Sedative depth was adequately achieved in all sedative treatments prior to removing the animal from the cage, as assessed using the sedative depth score, with ketamine and alfaxalone producing the greatest immediate effects (ketamine, 5 min: 16.8±0.7, \(P<0.0001\); alfaxalone, 5 min: 13.9±2.3, \(P<0.0001\)), followed by diazepam (10 min: 7.8±2.0, \(P = 0.0007\)), and midazolam (6 min: 7.1±2.0, \(P = 0.0038\)). Sedation under ketamine and alfaxalone remained highly significant from control throughout physiological monitoring (P1: ketamine, 12 min:13.0±2.4, \(P<0.0001\); alfaxalone, 11 min: 10.6±1.8, \(P = 0.0002\); P2: ketamine, 19 min: 13.5±2.6, \(P<0.0001\); alfaxalone, 16 min: 10.9±2.6, \(P = 0.0005\)); and animals under ketamine remained highly sedated upon returning to cage (28 min: 12.7±2.4, \(P<0.0001\)), whereas sedation under alfaxalone reduced more rapidly toward conscious levels (22 min: 8.6±2.7, \(P = 0.0059\)). Sedation was less effective under both diazepam and midazolam. By ‘P1’ sedative depth was only slightly higher than control when animals were removed from cage, becoming less different as the sedative score rose in control animals as they relaxed during monitoring (control, 11 min: 3.5±2.4; diazepam, 17 min: 9.0±2.6, \(P = 0.0086\); midazolam, 11 min: 8.1±2.8, \(P = 0.04\)). Neither diazepam nor midazolam were significantly different from control by ‘P2’ (control, 18 min: 3.7±2.2; diazepam, 23 min: 7.1±3.2, \(P = 0.20\); midazolam, 17 min: 6.8±3.0, \(P = 0.24\)), however, diazepam became significantly different from control when returned to cage, primarily due to a reduction in control sedative score (control, 26 min: 2.9±2.2; diazepam, 32 min: 7.3±2.1, \(P = 0.016\)). Animals sedated with alfaxalone, diazepam and midazolam all experienced hyperreactivity to experimental implementation. Under alfaxalone, animals settled within 5 min, whereas under diazepam and, in particular, midazolam were more variable, with five animals excessively

**Table 3. Standardised score of cumulative sedative depth.**

| Treatment | Removed from Cage | P1 | P2 | Returned to Cage | End |
|-----------|-------------------|----|----|------------------|-----|
| Control   | 5.00 ± 0.00       | 10.50 ± 1.06 | 17.44 ± 2.02 | 25.5 ± 2.55 | 31.15 ± 2.59 |
| Score     | 2.3 ± 1.8         | 3.5 ± 2.4 | 3.7 ± 2.2 | 2.9 ± 2.2 | 2.3 ± 1.8 |
| Alfaxalone| Time 5.00 ± 0.00  | 10.50 ± 1.57 | 15.50 ± 1.57 | 22.30 ± 2.37 | 31.40 ± 3.15 |
|           | Score 13.9 ± 2.3*** | 10.6 ± 1.8*** | 10.9 ± 2.6*** | 8.6 ± 2.7**  | 1.3 ± 0.9 |
| Diazepam  | Time 10.25 ± 0.49 | 17.30 ± 1.54 | 23.20 ± 2.12 | 32.30 ± 3.18 | 44.10 ± 3.58 |
|           | Score 7.8 ± 2.0*** | 9.0 ± 2.6**  | 7.1 ± 3.2 | 7.3 ± 2.1*  | 3.9 ± 1.8 |
| Ketamine  | Time 5.00 ± 0.00  | 12.30 ± 1.54 | 18.45 ± 1.46 | 28.20 ± 2.31 | 47.05 ± 5.35 |
|           | Score 16.8 ± 0.7*** | 13.0 ± 2.4*** | 13.5 ± 2.6*** | 12.7 ± 2.4*** | 3.4 ± 2.0 |
| Midazolam | Time 5.50 ± 1.06  | 11.15 ± 1.17 | 17.05 ± 1.27 | 24.10 ± 1.38 | 32.55 ± 3.30 |
|           | Score 7.1 ± 2.0**  | 8.1 ± 2.8*  | 6.8 ± 3.0 | 5.5 ± 1.6 | 3.3 ± 1.1 |

All scores were 0 at Baseline. Time (min) started following injections, events standardised to 5 min intervals when scores of sedative depth were assessed. Key events during sedation included ‘removed from cage’ at which point animals were deemed sedated enough to begin physiological monitoring; ‘P1’ during which physiological measures were applied; ‘P2’, during late physiological monitoring; Returned to cage, when physiological measures were complete; and End whereupon animals were deemed to have recovered. Statistics compared to control.  
* \(P = 0.05\),  
** \(P = 0.001\),  
*** \(P = 0.0001\),  
**** \(P<0.0001\).  

https://doi.org/10.1371/journal.pone.0259559.t003
hypersensitive to noise and touch under midazolam, which lead to physiological measures being abandoned in three animals.

**Cardiorespiratory physiology**

**Heart rate.** HR was obtained for all animals during all experimental manipulations. HR of control animals during monitoring was 332±25 b.min⁻¹, with a significant difference between males and females (male-female HR difference: 36 b.min⁻¹; P = 0.04). This was the only sex difference across all measured physiological variables. Administration of all sedatives increased HR significantly above control levels (P<0.0001; Fig 3A). Ketamine eliciting the smallest increase in comparison to control (difference: 37.6 b.min⁻¹, P = 0.005), followed by alfaxalone (39.1 b.min⁻¹, P = 0.001), midazolam (49.6 b.min⁻¹, P = 0.0002), and diazepam (52.8 b.min⁻¹, P = 0.0002).

**Systolic blood pressure.** Control SBP was 74.5±9.9 mmHg. SBP did not significantly differ from control following treatment with any of the sedative agents tested (Fig 3B). Movement artifact in both control and sedated animals as a result of blood pressure cuff inflations meant that BP measures were not available for all animals. The number of animals with successful SBP measures was 7/12 (58%) control animals, 10/12 (83%) under alfaxalone, and 11/12 (92%) under each diazepam, ketamine, and midazolam.

**Microvascular perfusion.** Distal and proximal microvascular perfusion in sedated animals (any treatment) was not different compared to that observed in control animals (distal perfusion: P = 0.11 (Fig 4A); proximal perfusion: P = 0.43 (Fig 4B), respectively). While slightly higher under alfaxalone, ketamine, and midazolam (318 (±170) PU; 351 (±183) PU; 294 (±202.0) PU, respectively), whereas both control and diazepam remained less so (166 (±62) PU; 185 (±124) PU, respectively). These differences were subject to a high degree of variability. Proximal perfusion, however, was much more consistent both within and between treatments. Proximal perfusion of control animals was 103±53 PU; however, outliers were observed in all treatments except midazolam. Temperature at probe sites did not differ between treatments (Distal: 33.2 (±0.5) °C; Proximal: 34.1 (±2) °C). Attrition of the sedated state meant that stable perfusion was obtained in 11/12 (92%) animals under diazepam and ketamine, and 9 (75%)
under midazolam, whereas stable perfusion data was completed for the whole study in both alfaxalone and in control animals.

**Respiration.** Administration of sedatives reduced respiratory rate (RR) significantly below that of control animals ($P<0.0001$; Fig 5). RR in control animals was 120±10 breaths.min$^{-1}$. Respiratory rate under both diazepam and midazolam was not significantly different from control (109±7 breaths.min$^{-1}$ and 112±8 breaths.min$^{-1}$, respectively). Whereas, under ketamine, respiration was reduced significantly to 106±8 breaths.min$^{-1}$ ($P = 0.05$), with the greatest decrease in RR caused by alfaxalone (86±7 breaths.min$^{-1}$; $P<0.0001$). Due to the instability of the sedated state under midazolam, data for 11 (92%) animals was suitable for analysis.

**Study II: Normative systolic blood pressure**

Normative animals were similar in weight and age, to the animals involved in the sedation study (weight: 365.5±16.1g $P = 0.69$; age: 38±1d $P = 0.87$). Normative systolic blood pressure (SBP) was 60±4mmHg. When compared to the normative control group, all Study I groups displayed significantly higher SBP, including control (difference: 14.8mmHg, $P = 0.0047$). Alfaxalone was similarly different to the normative population as the control group (difference: 14.6; $P = 0.0015$), whereas ketamine produced the greatest difference in SBP (24.2mmHg, $P<0.0001$), with midazolam the second greatest difference (19.2mmHg, $P = 0.0002$), and diazepam presenting the least difference from the normative population (11.5mmHg, $P = 0.014$).

**Discussion**

The current study has demonstrated that ketamine and alfaxalone are the most effective sedatives for providing stable light sedation for short duration cardiorespiratory monitoring (<1h) in guinea pigs. Further, at the dosage tested, midazolam was ineffective in sedating guinea pigs for physiological assessment. While all sedatives modified cardiorespiratory control, these variables remained within normal physiological limits, with ketamine exerting the least effect.

**Sedative efficacy**

Sedation was most effectively achieved under ketamine. This was followed in efficacy by alfaxalone, with both agents producing rapid onset, reliable sedation and rapid recovery. In contrast,
both midazolam and diazepam produced a much more volatile sedative state, characterised by hypersensitivity to manipulations (excessive motor response to light touch), and variable sedative efficacy, as well as variable sedation onset. This was particularly apparent under midazolam to the extent that physiological characterisation was abandoned in a quarter of the animals. Hypersensitivity under midazolam has previously been observed in cats and dogs [20], and has also been reported in response to alfaxalone administration in cats, dogs and humans [5, 21]. Of the agents currently tested, only ketamine has analgesic properties [6]. As such, the lack of analgesic properties in midazolam, diazepam and alfaxalone likely contributed to this agitation. Restraint was required when applying ECG electrodes under alfaxalone, midazolam, and diazepam, but once applied, animals under alfaxalone, and to a lesser extent diazepam, rapidly settled into moderate sedation.

For a single drug, sedative effects vary widely between species, with some agents proving excellent in some species and inadequate in others [2, 20]. This depends to a degree on route of administration and concentration of dose, but is highly dependent on metabolism and bioavailability. Guinea pigs frequently produce varied and contrary responses to sedative and anaesthetic agents [2]. For example, when administered medetomidine, an alpha-2 agonist and commonly used sedative, a recent study failed to achieve effective sedation in three out of four guinea pigs [2]. Similarly, when reviewing 10 years of experience Green et al. [22] noted that ketamine was an ineffective sedative in absence of adjuvants such as opioids or hypnotics.
Although, as with the current study, sedation was still achieved with 40 mg.kg$^{-1}$ despite intact pain responses. While sedative duration was not reported by Green [22], the current study observed ketamine sedation persisting for ~40 min. Green et al. [22] further noted, despite its shortcomings, that ketamine alone was still more effective than alfaxalone (alfaxalone-alpha-dolone-Cremophor-EL, old formulation [5]). When combined with xylazine, ketamine became a more stable sedative across species, and this combination remains a favoured sedative mix in guinea pigs, despite well recognised cardio-depressive effects [1, 22].

The efficacy of benzodiazepines also varies according to species and is further influenced by the use of adjuvant drugs [23]. In guinea pigs, sedation can be achieved using midazolam in combination with medetomidine and fentanyl (MMF) [3]. However, as with ketamine-xylazine (KZ), MMF produces marked cardiorespiratory depression [3]. When used alone, midazolam is unreliable in cats and dogs, producing paradoxical excitement and aggression, but reliably induces sedation and muscle relaxation in swine, ferrets and birds [20]. The hypersensitivity to stimuli observed under midazolam in the current study appears to align with the findings in cats and dogs [21]. Interestingly, the current study did not observe hypersensitivity with diazepam, despite it belonging to the same family. As such, in guinea pigs ketamine and alfaxalone sedation proved most reliable.

**Physiological effects**

While sedative depth is important for maintaining a stable compliant subject, the dosages and combinations of agents frequently come at the cost of cardiovascular and respiratory stability, as with KZ, and MMF [3]. The current study aimed to identify an effective agent for minimally invasive physiological monitoring that balanced these two needs. Indeed, none of the agents at the doses currently used produced dramatic changes in cardiovascular variables, and alfaxalone alone reduced respiration in a highly significant manner, albeit still well within normal ranges expected of guinea pigs [15].

All sedative agents currently investigated significantly increased HR. Diazepam and midazolam increased HR to a greater degree than alfaxalone and ketamine. Such effects have previously been ascribed to alterations in vascular tone [6, 24, 25], despite no differences observed in the cutaneous microvasculature nor blood pressure during the current study. Cardiovascular depression is commonly noted with most sedative agents including alfaxalone and diazepam or midazolam [26], with commonly used adjuvants potentiating their effects [27]. Ketamine acts directly and indirectly on the cardiovascular system to simultaneously depress and enhance function [6], such that its cardiovascular effects are minimal, and are only observed when an adjuvant exacerbates its efficacy (e.g., KZ [22]). Alfaxalone is increasingly used as a sedative as it also has limited cardiovascular effects [5, 24, 28–30]. However, alfaxalone does elicit dose-dependent respiratory depression [5, 30], as observed within the current study. Despite this, respiration remained within normal limits reported for guinea pigs (range: 40–130 breaths.min$^{-1}$) [15]. The increased HR under alfaxalone was also observed in dogs (at 2 and 6 mg.kg$^{-1}$), with Muir et al. [5] corroborating other findings [24, 25], suggesting this was due to decreased peripheral vascular resistance, secondary to vasodilation. Conversely, in a recent study of guinea pigs, d’Ovidio et al. [8] observed no cardiorespiratory effects of alfaxalone at the same dosage used currently. The benzodiazepines used in the current study had the most pronounced effects on HR. This is likely through a similar mechanism as Muir et al. [5] identified in alfaxalone, as benzodiazepines are known to produce vasodilation [6].

Resting normative blood pressure in the current study (Study II) was 60 mmHg, which is consistent with previous findings (~66 mmHg) [3]. However, when compared to the normative control group (Study II), SBP was higher in Study I control animals, likely due to a
sequencing effect, whereby SBP was assessed following instrumentation of animals, whereas in Study II, animals had no injections or ECG or Doppler probe placement to confound readings. Systolic blood pressure in Study I remained unaffected by any of the currently used agents in comparison to control, despite any effects on HR and vasculature. As handling stress of the procedure was reduced, indicated by sedative depth, it is likely that a combination of a remainder of stress that the drugs did not remove, plus haemodynamic factors, such as peripheral dilation contributing to increased HR, maintained a slightly elevated SBP compared to the normative population. The greater variability in SBP observed during Study I reflects the inter-subject variability in sedative efficacy and stress of comprehensive physiological monitoring.

**Limitations**

Diazepam and ketamine have recently been demonstrated to cause irritation and even tissue necrosis when administered SC or IM [9, 10]. Further, ketamine has been shown to be neurotoxic in both young and mature animals [7, 31], precluding their use as sedative agents [10]. The current study involved no formal assessments of behaviour, however, we observed no changes in animal behaviour (B.A.R. score) during the study period, suggesting no signs of neurodegeneration. This, however, does not discount that potential toxic effects would not have been observed histologically, with formal assessments, or after greater periods of time. Injection of diazepam and midazolam did result in acute irritation of the injection site, with animals often licking and biting at injection sites upon arousal, though this did not result in prolonged observable effects (all recovered by following day). As such, utilising ketamine or diazepam as an IM sedative agent for physiological assessments should only be performed in diluted, pH balanced quantities or in non-survival studies, to reduce the risk of their potential deleterious effects [10].

In contrast to ketamine, alfaxalone has been demonstrated to be safe in both young and mature animals [5, 8, 32, 33], despite GABAergic agents commonly being associated with neurotoxicity [34]. This is likely due to its neurosteroid properties [5, 8]. Additionally, alfaxalone has been shown to have no deleterious effects from repeat administration [35]. This makes alfaxalone more appropriate for studies requiring repeated physiological monitoring.

Alfaxalone, midazolam and diazepam have limited analgesic effects, and are therefore frequently paired with analgesic drugs. Indeed, in the current study, when applying the ECG needle electrodes, the painful stimulus may have led to increased arousal and a hyperresponsivity under all three agents. However, the purpose of the current study was to examine the capacity of the drug per se to facilitate physiological examination, and under situations where reducing the state of anxiety did not impair homeostatic functioning. Furthermore, the wide range of formulations (combination, or alone), differences in dosage and in the route of administration impair assessment of the efficacy of particular sedative agents. Adjuvants additionally interact to compound the sedated state, and depress cardiorespiratory function [1, 27, 36]. As such, additional agents were deemed to be a confounding influence and primarily deleterious in a study where analgesia was not required.

**Conclusions**

Achieving a stable depth of sedation to enable detailed, physiologically robust, cardiorespiratory characterisation remains challenging, especially in species like the guinea pig. Ketamine and alfaxalone produced the most stable sedation. However, the potential risks of neurotoxicity of ketamine and diazepam when administered IM may limit their use in repeated physiological monitoring. Furthermore, while benzodiazepines are effective as anxiolytics in some
species, humans included, their sole use is not recommended in guinea pigs. Despite the limitations, most sedatives still enable more detailed physiological monitoring than can be reliably achieved in conscious animals. In conclusion, alfaxalone proved to be the most effective in juvenile guinea pigs and induced stable, short-acting sedation for physiological monitoring.

**Supporting information**

S1 Table. Monitored signs of movement and attrition rate during sedation with intramuscular sedatives.
(DOCX)

S2 Table. Monitored signs of body tone and attrition rate during sedation with intramuscular sedatives.
(DOCX)

S3 Table. Monitored signs of reaction to manipulation and attrition rate during sedation with intramuscular sedatives.
(DOCX)

S4 Table. Monitored signs of posture and attrition rate during sedation with intramuscular sedatives.
(DOCX)

S5 Table. Monitored signs of righting reflex and attrition rate during sedation with intramuscular sedatives.
(DOCX)

**Acknowledgments**

We acknowledge Maureen Prowse (Department of Paediatrics) for her contribution to the animal work, and Dr Alyssa Calder (Animal Welfare Officer, University of Otago) for her assistance with sedative selection and advice on dosing and study design.

**Author Contributions**

**Conceptualization:** Ryan P. Sixtus, Mary J. Berry, Rebecca M. Dyson.

**Data curation:** Ryan P. Sixtus.

**Formal analysis:** Ryan P. Sixtus.

**Funding acquisition:** Mary J. Berry, Rebecca M. Dyson.

**Investigation:** Ryan P. Sixtus, Rebecca M. Dyson.

**Methodology:** Ryan P. Sixtus, Cholawat Pacharinsak, Rebecca M. Dyson.

**Project administration:** Ryan P. Sixtus, Rebecca M. Dyson.

**Validation:** Ryan P. Sixtus, Clint L. Gray, Rebecca M. Dyson.

**Visualization:** Ryan P. Sixtus.

**Writing – original draft:** Ryan P. Sixtus.

**Writing – review & editing:** Cholawat Pacharinsak, Clint L. Gray, Mary J. Berry, Rebecca M. Dyson.
References

1. Schwenke DO, Cragg PA. Comparison of the depressive effects of four anesthetic regimens on ventila-
tory and cardiovascular variables in the guinea pig. Comp Med. 2004; 54(1):77–85. Epub 2004/03/19. 
PMID: 15027622.

2. Dang V, Bao S, Ault A, Murray C, McFarlane-Mills J, Chiedi C, et al. Efficacy and safety of five injectable 
anesthetic regimens for chronic blood collection from the anterior vena cava of Guinea pigs. J Am 
Assoc Lab Anim Sci. 2008; 47(6):56–60. Epub 2008/12/04. PMID: 19049255; PubMed Central PMCID: 
PMC2687127.

3. Schmitz S, Tacke S, Guth B, Henke J. Comparison of Physiological Parameters and Anaesthesia Spec-
cific Observations during Isoflurane, Ketamine-Xylazine or Medetomidine-Midazolam-Fentanyl Anaes-
thesia in Male Guinea Pigs. PLoS One. 2016; 11(9):e0161258. https://doi.org/10.1371/journal.pone. 
0161258 PMID: 27658033; PubMed Central PMCID: PMC5033476 not alter the authors’ adherence to 
PLOS ONE policies on sharing data and materials. None of the authors currently serve as editorial 
board members to PLOS ONE, have acted as an expert witness in relevant legal proceedings or cur-
rrently sit on a committee for an organization that might benefit from the publication of this data.

4. Sixtus RP, Gray C, Berry MJ, Dyson RM. Nitrous oxide improves cardiovascular, respiratory, and ther-
mal stability during prolonged isoflurane anesthesia in juvenile guinea pigs. Pharmacol Res Perspect. 
2021; 9(1):e00713. Epub 2021/02/06. https://doi.org/10.1002/prp2.713 PMID: 33543602; PubMed Central 
PMCID: PMC7862177.

5. Muir W, Lerche P, Wiese A, Nelson L, Pasloske K, Whitem T. Cardiorespiratory and anesthetic effects of 
clinical and supraclinical doses of alfaxalone in dogs. Vet Anaesth Analg. 2008; 35(6):451–62. Epub 
2008/09/17. https://doi.org/10.1111.j.1467-2995.2008.00406.x PMID: 18793290.

6. Farag E, Argaliou M, Tetzlaff JE, Sharma D. Basic Sciences in Anesthesia. Farag E, Argaliou M, Tet-
zlaff JE, Sharma D, editors. Switzerland: Springer; 2018.

7. Jevtovic-Todorovic V, Wozniak DF, Benshoff ND, Olney JW. A comparative evaluation of the neurotoxic 
properties of ketamine and nitrous oxide. Brain Res. 2001; 895(1–2):264–7. Epub 2001/03/22. https://

8. d’Ovidio D, Marino F, Noviello E, Lanaro E, Monticelli P, Adami C. Sedative effects of intramuscular 
alfaxalone in pet guinea pigs (Cavia porcellus). Veterinary Anaesthesia and Analgesia. 2018; 45 
(2):183–9. https://doi.org/10.1016/j.vaa.2017.10.004 PMID: 29399530.

9. Flecknell P. Laboratory Animal Anaesthesia. 4 ed. Audel J, editor. United Kingdom: Academic Press, 
Elsevier; 2016. 350 p.

10. Anonymous. Diagnosis | Self-mutilation after intramuscular ketamine-related neuronal injury. Lab Ani-
mal. 2011; 40(7):214–6. https://doi.org/10.1038/laban0711-214

11. Radde GR, Hinson A, Crenshaw D, Toth LA. Evaluation of anesthetic regimens in guinea pigs. Lab Anim. 
1996; 30(3):220–7. https://doi.org/10.1258/00236779678068935 PMID: 8843046.

12. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: 
the ARRIVE guidelines for reporting animal research. Osteoarthritis and cartilage. 2012; 20(4):256–60. 
https://doi.org/10.1016/j.joca.2012.02.010 PMID: 2244462

13. Altman DG, Bland JM. Treatment allocation by minimisation. BMJ. 2005; 330(7495):843. https://doi.org/ 
10.1136/bmj.330.7495.843 PMID: 15817555

14. Weeks KL, Hentridge DC, Salim A, Shaw JE, Marwick TH, McMullen JR. CORP: Practical tools for 
improving experimental design and reporting of laboratory studies of cardiovascular physiology and 
metabolism. Am J Physiol Heart Circ Physiol. 2019; 317(3):H627–H39. Epub 2019/07/28. https://doi. 
org/10.1152/ajpheart.00327.2019 PMID: 31347916.

15. Hrapkiewicz K, Colby L, Denison P. Guinea pigs. In: Hrapkiewicz K, Colby L, Denison P, editors. Clinical 
Laboratory Animal Medicine: An Introduction. United Kingdom: John Wiley & Sons, Inc; 2013.

16. Shiotani M, Harada T, Abe J, Hamada Y, Horii I. Methodological validation of an existing telemetry sys-
tem for QT evaluation in conscious guinea pigs. J Pharmacol Toxicol Methods. 2007; 55(1):27–34. 
Epub 2006/07/13. https://doi.org/10.1016/j.j.vascn.2006.04.008 PMID: 16831559.

17. Dyson RM, Palliser HK, Lakkundi A, de Waal K, Latter JL, Clifton VL, et al. Early microvascular changes 
in the preterm neonate: a comparative study of the human and guinea pig. Physiol Rep. 2014; 2(9). 
https://doi.org/10.14814/phy2.12145 PMID: 25350751; PubMed Central PMCID: PMC4270232.

18. Rajan V, Varghese B, van Leeuwen TG, Steenbergen W. Review of methodological developments in 
laser Doppler flowmetry. Lasers Med Sci. 2009; 24(2):269–83. Epub 2008/02/01. https://doi.org/10. 
1007/s10103-007-0524-0 PMID: 18236103.

19. Roustit M, Blaise S, Millet C, Cracowski JL. Reproducibility and methodological issues of skin post-
occlusive and thermal hyperemia assessed by single-point laser Doppler flowmetry. Microvasc Res. 
2010; 79(2):102–8. Epub 2010/01/13. https://doi.org/10.1016/j.mvr.2010.01.001 PMID: 20064535.
20. Lemke KA. Anticholinergics and sedatives. 2007. In: Lumb & Jones’ Veterinary Anesthesia and Analgesia [Internet]. Ames, IA: Blackwell Publishing; [229–30].

21. Prys-Roberts C, Sear JW. Steroid Anaesthesia. Br J Anaesth. 1980; 52:363–5. https://doi.org/10.1093/bja/52.4.363 PMID: 7378235

22. Green CJ, Knight J, Precious S, Simpkin S. Ketamine alone and combined with diazepam or xylazine in laboratory animals: a 10 year experience. Lab Anim. 1981; 15:163–70. https://doi.org/10.1258/002367781780959107 PMID: 7278122

23. Mans C, Guzman DS-M, Lahner LL, Paul-Murphy J, Sladky KK. Sedation and Physiologic Response to Manual Restraint After Intranasal Administration of Midazolam in Hispaniolan Amazon Parrots (Amazona ventralis). Journal of Avian Medicine and Surgery. 2012; 26(3):130–9. https://doi.org/10.1647/2011-037R.1 PMID: 23156974

24. Pfeiffer N, Ebner J, von T, Schuster, Erhardt, Baumgartner. Cardiovascular effects of alfaxalone on hemodynamic function in pigs. Open Access Animal Physiology. 2013. https://doi.org/10.2147/oaap.S46325

25. Ambrose B, Duke-Novakovski T, Pasloske KS. Comparison of the anesthetic efficacy and cardiopulmonary effects of continuous rate infusions of alfaxalone-2-hydroxypropyl-beta-cyclodextrin and propofol in dogs. Am J Vet Res. 2008; 69(11):1391–8. https://doi.org/10.2460/ajvr.69.11.1391 PMID: 18980420

26. Kurz A, Sessler DI, Annadata R, Dechert M, Christensen R, Bjorksten AR. Midazolam Minimally Impairs Thermoregulatory Control. Anesthesiology. 1995; 81(2):393–9. https://doi.org/10.1097/00000539-199508000-00032 PubMed PMID: WOS:A1995RL64500032. PMID: 7618734

27. Hall RW, Shbarou RM. Drugs of choice for sedation and analgesia in the NICU. Clinics in perinatology. 2009; 36(1):15. https://doi.org/10.1016/j.clp.2008.09.007 PMID: 19161862

28. Pearson M, Best P, Patten B, editors. New therapeutic horizons: choosing a new drug for inducing anesthesia: propofol or alfaxalone. Proceedings of the American Academy of Veterinary Pharmacology and Therapeutics Thirteenth Biennial Symposium; 2003; Charlotte, NC.

29. Jones KL. Therapeutic reviews: alfaxalone. J Exotic Pet Med. 2012; 21:34–53.

30. Ishikawa Y, Sakata H, Tachibana Y, Itami T, Oyama N, Umar MA, et al. Sedative and physiological effects of low-dose intramuscular alfaxalone in rabbits. J Vet Med Sci. 2019; 81(6):851–6. Epub 2019/05/08. https://doi.org/10.1292/jvms.18-0618 PMID: 31061294; PubMed Central PMCID: PMC6612508.

31. Scallet AC, Schmued LC, Slikker W Jr., Grunberg N, Faustino PJ, Davis H, et al. Developmental neurotoxicity of ketamine: morphometric confirmation, exposure parameters, and multiple fluorescent labeling of apoptotic neurons. Toxicol Sci. 2004; 81(2):364–70. Epub 2004/07/16. https://doi.org/10.1093/toxsci/kfh224 PMID: 15254342.

32. O’Hagan B, Pasloske K, McKinnon C, Perkins N, Whittam T. Clinical evaluation of alfaxalone as an anaesthetic induction agent in dogs less than 12 weeks of age. Aust Vet J. 2012; 90(9):346–50. Epub 2012/08/30. https://doi.org/10.1111/j.1751-0813.2012.00974.x PMID: 22928682.

33. O’Hagan BJ, Pasloske K, McKinnon C, Perkins NR, Whittam T. Clinical evaluation of alfaxalone as an anaesthetic induction agent in cats less than 12 weeks of age. Aust Vet J. 2012; 90(10):395–401. Epub 2012/09/26. https://doi.org/10.1111/j.1751-0813.2012.00983.x PMID: 23004232.

34. Jevtovic-Todorovic V. General Anesthetics and Neurotoxicity: How Much Do We Know? Anesthesiol Clin. 2016; 34(3):439–51. Epub 2016/08/16. https://doi.org/10.1016/j.anclin.2016.04.001 PMID: 27521190; PubMed Central PMCID: PMC5477636.

35. Whittam T, Pasloske KS, Heit MC, Ranasinghe MG. The pharmacokinetics and pharmacodynamics of alfaxalone in cats after single and multiple intravenous administration of Alfaxon at clinical and supraclinical doses. J Vet Pharmacol Ther. 2008; 31(6):571–9. Epub 2008/11/13. https://doi.org/10.1111/j.1365-2885.2008.00998.x PMID: 1900281.

36. Higuchi S, Yamada S, Hashimoto A, Miyoshi K, Yamashita K, Ohsugi T. Evaluation of a combination of alfaxalone with medetomidine and butorphanol for inducing surgical anesthesia in laboratory mice. Jpn J Vet Res. 2016; 64:131–9. PMID: 27506087